Roche is studying satralizumab in additional neurologic, autoimmune, and inflammatory conditions that may benefit from interleukin-6 signaling inhibition

Health

Health news, debates, and claims covering public health, mental health, nutrition, medical care, and health policy.

1 debate·6,984 claims·43 news stories